4.4 Editorial Material

Pembrolizumab: first adjuvant immunotherapy in renal cell carcinoma?

Journal

FUTURE ONCOLOGY
Volume 18, Issue 5, Pages 519-522

Publisher

FUTURE MEDICINE LTD
DOI: 10.2217/fon-2021-1309

Keywords

immunotherapy; ipilimumab; nivolumab; pembrolizumab; renal cell carcinoma; tyrosine kinase inhibitor

Categories

Ask authors/readers for more resources

The optimal sequencing and combination of ICIs to enhance oncologic outcomes for these patients remains a million-dollar question, as it is challenging to strike a delicate balance between utilizing the right window of opportunity to cure the disease and jeopardizing proven therapies for metastatic disease.
The million-dollar question remains the optimal sequencing and combination of ICIs to optimize oncologic outcomes for these patients. The big challenge lies in defining the thin line between utilizing the right window of opportunity to cure disease and jeopardizing proven therapies for metastatic disease

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available